Vestcor Inc Grows Holdings in Vertex Pharmaceuticals Incorporated

Pharmaceutical company Vertex sees increased investment from Vestcor Inc.

Published on Mar. 9, 2026

Got story updates? Submit your updates here. ›

Vestcor Inc., an investment management firm, has increased its stake in Vertex Pharmaceuticals Incorporated, a Boston-based biotechnology company focused on developing therapies for serious diseases like cystic fibrosis. According to a recent SEC filing, Vestcor grew its position in Vertex by 12% in the third quarter, now owning 35,266 shares worth $13.8 million.

Why it matters

Vertex Pharmaceuticals is a leader in the development of cystic fibrosis treatments, an area of significant unmet medical need. The increase in Vestcor's investment signals confidence in Vertex's pipeline and future growth prospects as the company continues to advance its research and commercialize new therapies.

The details

In its SEC filing, Vestcor reported acquiring an additional 3,778 shares of Vertex Pharmaceuticals in the third quarter, bringing its total holdings to 35,266 shares. This represents a 12% increase in Vestcor's position in the pharmaceutical company. Vertex Pharmaceuticals is known for its portfolio of small-molecule CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

  • Vestcor Inc. grew its position in Vertex Pharmaceuticals in the third quarter of 2026.

The players

Vestcor Inc.

An investment management firm that has increased its stake in Vertex Pharmaceuticals Incorporated.

Vertex Pharmaceuticals Incorporated

A Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases, particularly cystic fibrosis.

Got photos? Submit your photos here. ›

The takeaway

Vestcor's increased investment in Vertex Pharmaceuticals suggests confidence in the company's ability to continue advancing its pipeline of cystic fibrosis treatments and drive future growth. As a leader in this therapeutic area, Vertex's progress will be closely watched by investors and the broader healthcare community.